LivingGLP1
Study S000022

LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors

Included trial: extracted dataClinicalTrials.gov recordStudy Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration
NCT02964247
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE3
Masking
DOUBLE
Status
COMPLETED
Enrollment
303
Start
2017-03-03
Primary completion
2018-05-04
Lead sponsor
Novo Nordisk A/S
Conditions
Diabetes; Diabetes Mellitus, Type 2
Interventions
DRUG:liraglutide; DRUG:placebo
Results posted
TRUE
Individual participant data sharing
YES
Secondary identifiers
OTHER:U1111-1184-8086

Registered primary outcomes

  • Change in HbA1c [Week 0, Week 26]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0024029Efficacy of liraglutide added to sodium-glucose cotransporter-2 inhibitors in type 2 diabetes, stratified by baseline characteristics: Post-hoc analysis of LIRA-ADD2SGLT2i.
Blonde L, Diabetes, obesity & metabolism
2021Randomized trialPMID 34132018DOIcites ClinicalTrials.gov:NCT02964247; registry reference DERIVED:34132018
R0024267Liraglutide as add-on to sodium-glucose co-transporter-2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA-ADD2SGLT2i, a 26-week, randomized, double-blind, placebo-controlled trial.
Blonde L, Diabetes, obesity & metabolism
2020Randomized trialPMID 31984646DOIregistry reference RESULT:31984646
R0024928OR22-1 Liraglutide as Add-on to SGLT2 Inhibitors in Patients with Inadequately Controlled Type 2 Diabetes (LIRA-ADD2SGLT2i): A 26-Week, Randomized, Double-Blind, Placebo-Controlled Trial
Blonde L, Journal of the Endocrine Society
2019Randomized trialDOIcites ClinicalTrials.gov:NCT02964247